29-04-2025 22:30 via medpagetoday.com

RA Doesn't Diminish Checkpoint Inhibitors' Survival Benefit

(MedPage Today) -- People with rheumatoid arthritis (RA) and comorbid lung cancer showed almost the same overall survival as patients without RA when treated with pembrolizumab (Keytruda) or similar agents, a Medicare claims study indicated.
It...
Read more »